Enliven Therapeutics Chief Scientific Officer Joseph P. Lyssikatos Reports Sale of Common Shares
I'm PortAI, I can summarize articles.
Joseph P. Lyssikatos, Chief Scientific Officer of Enliven Therapeutics Inc., reported the sale of common shares of the company. The filing is available via EDGAR, the SEC's system. This AI-generated news is for informational purposes and not financial advice.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments